What is it used for?
RUBRACA is indicated for the treatment of adult patients with a deleterious BRCAmutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy. Select patients for therapy based on an FDA-approved companion diagnostic for RUBRACA .RUBRACA is indicated for the treatment of adult patients with a deleterious BRCAmutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy. Select patients for therapy based on an FDA-approved companion diagnostic for RUBRACA .
Read the primary sourceThis source does not establish current stock, import permission or personal eligibility in China. The treating clinician and provider must confirm these separately.
Product details
- Active ingredient
- rucaparibrucaparib
- Form and strength
- TABLET, FILM COATED · 200 mg; TABLET, FILM COATED · 300 mg; TABLET, FILM COATED · 250 mgTABLET, FILM COATED · 200 mg; TABLET, FILM COATED · 300 mg; TABLET, FILM COATED · 250 mg
- Manufacturer / applicant
- PHARMAAND GMBHPHARMAAND GMBH
Tablets (200 mg): blue, round, immediate-release, film-coated, debossed with “C2”. Tablets (250 mg): white, diamond, immediate-release, film-coated, debossed with “C25”. Tablets (300 mg): yellow, oval, immediate-release, film-coated, debossed with “C3”.Tablets (200 mg): blue, round, immediate-release, film-coated, debossed with “C2”. Tablets (250 mg): white, diamond, immediate-release, film-coated, debossed with “C25”. Tablets (300 mg): yellow, oval, immediate-release, film-coated, debossed with “C3”.
Safety and clinical review
Ask your clinician to review the complete label, medical history, other medicines, allergies, pregnancy or breastfeeding and any required monitoring. Do not start, stop or change treatment from this page.
Read the primary sourcePrepare your enquiry
Include the brand or generic name, strength, dosage form, requested quantity and country where care is needed. You can attach a prescription when you continue.
Questions patients ask
What is Rubraca used for?
RUBRACA is indicated for the treatment of adult patients with a deleterious BRCAmutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy. Select patients for therapy based on an FDA-approved companion diagnostic for RUBRACA .RUBRACA is indicated for the treatment of adult patients with a deleterious BRCAmutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy. Select patients for therapy based on an FDA-approved companion diagnostic for RUBRACA .
This source does not establish current stock, import permission or personal eligibility in China. The treating clinician and provider must confirm these separately.
Which formulation of Rubraca should I ask about?
TABLET, FILM COATED · 200 mg; TABLET, FILM COATED · 300 mg; TABLET, FILM COATED · 250 mgTABLET, FILM COATED · 200 mg; TABLET, FILM COATED · 300 mg; TABLET, FILM COATED · 250 mg
Read the primary sourceWhat determines the price of Rubraca?
A current quote depends on the exact presentation, quantity, provider and access arrangements. A catalogue entry is not a stock or delivery promise. Medical charges are paid to the provider, separately from coordination fees.
What should I check before using Rubraca?
Ask your clinician to review the complete label, medical history, other medicines, allergies, pregnancy or breastfeeding and any required monitoring. Do not start, stop or change treatment from this page.
Sources and review scope
FDA prescribing informationThis source does not establish current stock, import permission or personal eligibility in China. The treating clinician and provider must confirm these separately.